Endothelial dysfunction plays a key role in obesity-induced risk of cardiovascular disease. The aim of the present study was to analyze the effect of chronic peroxisome proliferator-activated receptor (PPAR)β/δ agonist GW0742 treatment on endothelial function in obese mice fed a high-fat diet (HFD).
Five-week-old male mice were allocated to one of the following groups: control, control-treated (GW0742, 3 mg/kg per day, by oral gavage), HFD, HFD + GW0742, HFD + GSK0660 (1 mg/kg/day, intraperitoneal) or HFD-GW0742-GSK0660 and followed for 11 or 13 weeks. GW0742 administration to mice fed HFD prevented the gain of body weight, heart and kidney hypertrophy, and fat accumulation. The increase in plasma levels of fasting glucose, glucose tolerance test, homeostatic model assessment of insulin resistance, and triglyceride found in the HFD group was suppressed by GW0742. This agonist increased plasma HDL in HFD-fed mice and restored the levels of tumor necrosis factor-α and adiponectin in fat. GW0742 prevented the impaired nitric oxide-dependent vasodilatation induced by acetylcholine in aortic rings from mice fed HFD. Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-α, and interleukin-6 expression, and IκBα phosphorylation found in aortae from the HFD group. GSK0660 prevented all changes induced by GW0742.
PPARβ/δ activation prevents obesity and exerts protective effects on hypertension and on the early manifestations of atherosclerosis, that is, endothelial dysfunction and the vascular pro-oxidant and pro-inflammatory status, in HFD-fed mice.
aDepartment of Pharmacology, School of Pharmacy
bCIBER-EHD, Department of Pharmacology, Center for Biomedical Research, University of Granada, Armilla, Granada
cDepartment of Physiology, University of Valencia, Valencia
dDepartment of Pharmacology, School of Medicine, University Complutense of Madrid, Madrid, Spain
*Marta Toral and Manuel Gómez-Guzmán contributed equally to the writing of this article.
Correspondence to Juan Duarte, Department of Pharmacology, School of Pharmacy, University of Granada, 18071 Granada, Spain. Tel: +34 958241791; fax: +34 958248264; e-mail: email@example.com
Abbreviations: ABCG1, ATP-binding cassette transporter G1; Akt, protein kinase B; Cav-1, caveolin-1; CPT-1, carnitine palmitoyltransferase 1; DAPI, 4,6-diamidino-2-phenylindole dichlorohydrate; DHE, dihydroethidium; DMSO, dimethylsulfoxide; eNOS, endothelial nitric oxide synthase; GTT, glucose tolerance test; HFD, high-fat diet; HOMA-IR, homeostatic model assessment of insulin resistance; JNKs, c-Jun N-terminal kinases; L-NAME, NG-nitro-L-arginine methyl ester; LPS, lipopolysaccharide; NF-κB, redox-sensitive nuclear factor-κB; O2.-, superoxide; PDK4, pyruvate dehydrogenase kinase 4; PEG-SOD, pegylated superoxide dismutase; PPARs, peroxisome proliferator-activated receptors; ROS, reactive oxygen species; RPL13, ribosomal protein L13; RT-PCR, reverse transcriptase-PCR; SOD, superoxide dismutase; STZ, streptozotocin; TLR4, Toll-like receptor 4; UCP2, uncoupling protein-2
Received 5 September, 2014
Revised 15 April, 2015
Accepted 15 April, 2015
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.jhypertension.com).